|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 10, 2017 ) Dengue fever is also known as break bone fever, it is a mosquito born and endemic disease that leads to severe flu like illness. Dengue caused by RNA virus dengue belongs to the family Flaviviridae. Dengue is spread by several mosquito species of the Aedes type, mainly by A. aegypti. Symptoms include fever, muscle and joint pains, headache vomiting, and characteristic skin rash. With proper treatment, dengue patient can recover from the infection within seven days. However, in some cases, it may lead to life threatening dengue hemorrhagic fever. Dengue virus has five different types of strains, infection with one strain of dengue virus usually gives lifelong immunity to that type. Subsequent infection with a different type of dengue virus increases the risk of severe complications.
Global dengue vaccine market is expected to grow over the forecast period owing to frequent incidences of dengue infections in tropical and sub-tropical regions, and increased government funding to develop vaccines. According to World Health Organization (WHO), 50 to 100 Mn dengue infections occur yearly. In addition, market players are actively involved in partnerships with NGO’s and government organisations, few vaccines are under clinical trials and rise in medical insurance in developing countries are anticipated to drive the market over the forecast period. However, lack or insufficient healthcare infrastructure in underdeveloped and developing regions leading to serious medical conditions going unnoticed. Furthermore, lack of awareness related to symptoms and high cost of vaccine development are hindering the dengue vaccine market.
A sample of this report is available upon request @ <||>rnhttps://www.precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/#ulp-4H8Z4LpNMLEuOnnx
Dengue vaccine market segmented on the basis of vaccine type and end-user
Based on vaccine type, dengue vaccine market is segmented into
• Live- Attenuated Vaccines
• Purified Inactivated Vaccines
Based on end-user, dengue vaccine market is segmented into
• Hospitals
• Clinics
• Others
Dengue vaccine market is expected to grow at a significant rate during the forecast period. Market players are focusing on the development of dengue vaccines which are in different stages of development to grab the market share. For instance, TDEN PIV, a tetravalent purified inactivated vaccine for prevention of dengue, currently being developed jointly by alter Reed Army Institute of Research (WRAIR) and GSK in phase -1 clinical study. Similarly, TDV is a live attenuated vaccine that is being developed in phase-3 clinical trials by Takeda Pharmaceuticals. Furthermore, many research institutions such as Bhutantan Institute, Griffith University are involved in development of dengue vaccine. Government and non-government organizations initiating many programs and activities to increase vaccines usage and awareness among the people.
To view TOC of this report is available upon request @ <||>rnhttps://www.precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/#ulp-c654SbFYO64MsOhu
Geographically dengue vaccine market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East &Africa. North America dengue vaccine market is expected to show significant growth rate owing to new vaccine launches and growing awareness and government initiatives to prevent the dengue. In September 2016, Sanofi launched dengvaxia in Mexico for prevention of dengue. Asia Pacific region dengue vaccine market expected to grow at a high rate due to increase in dengue coupled with an increase in government funding for dengue vaccination. In April 2016, The Philippines government initiated vaccination program for prevention of dengue. South East Asia and Western Pacific regions are more seriously affected by dengue.
Some of the market players in Dengue Vaccine Market include Sanofi (France), GlaxoSmithKline Plc (London), Takeda Pharmaceutical Company Ltd (Japan), Merck & Co Inc. (U.S.), Instituto Butantan (Brazil), and VABIOTECH (Vietnam) to name a few.
Need more information about this report @ <||>rnhttps://www.precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/#ulp-14mlyhjMGhVjZqa3
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.
Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
Precision Business Insights
Sales
+1-866-598-1553
sales@precisionbusinessinsights.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
